Table 1. Clinical, immunological profiles and functional respiratory tests characteristic of patients with systemic sclerosis (SSc).
| Clinical characteristics | |||
| Age, y | (mean ± sd) | 54.5±12 | |
| Female, n(%) | 43 (93) | ||
| Classification of scleroderma spectrum of disease, n (%) | |||
| Diffuse scleroderma | 9 (19) | ||
| Limited scleroderma | 33 (72) | ||
| Overlap syndrome | 4 (9) | ||
| Skin involvement, Rodnan score (mean ± sd) | 9.3 ±7.5 | ||
| Digital ulcers, n (%) | |||
| evolutive | 5 (11) | ||
| previous | 15 (33) | ||
| Articular involvement, n (%) | 15 (33) | ||
| Pulmonary fibrosis, n (%) | 1 (2) | ||
| Pumonary hypertension, n (%) | 2 (4) | ||
| associated with pulmonary fibrosis | 1 (2) | ||
| isolated | 1 (2) | ||
| Digestive complications, n (%) | 18 (39) | ||
| Associated Sjögren syndrome, n (%) | 9 (19) | ||
| Functional respiratory tests characteristics | |||
| FVC (liters mean ± sd; % mean ± sd) | 3.45±0.89 | 110±16.2 | |
| DLCO (CO ml/min/mmHg mean ± sd; % of predicted) | 18.6±4.47 | 76.5±13.5 | |
| DLCO/VA (% of predicted) | 88.7±15.4 | ||
| 6 month-previous DLCO/VA (% of predicted) | 86.2±15.9 | ||
| 6 minutes walk test (meters mean ± sd; % of predicted) | 440.45±97.8 | 84.4±11.2 | |
| Immunological characteristics | |||
| Anti-nuclear Ab, n (%) | 44 (96) | ||
| Anti-Scl70 Ab, n (%) | 3 (7) | ||
| Anti-centromere Ab, n (%) | 33 (71) | ||
| Anti-cardiolipin Ab, n (%) | 8 (17) | ||
FVC: forced vital capacity, DLCO: diffusing lung factor for carbon monoxide, DLCO/VA diffusing capacity divided by the alveolar volume. sPAP: Systolic pulmonary artery pressure at right heart catheterism. Ab: antibodies.